WHWK

Whitehawk Therapeutics Inc (WHWK) Economic Moat Analysis (2026)

Invetso Score: 2.6/10 — Weak · Last Updated: 2026-08-01

Overall Score

Scale Market Position

Micro-cap scale limits pricing power and competitive positioning.

No evidence of durable market share leadership or network effects.

Profitability Returns

TTM margins are effectively zero, with negative net income and operating profitability.

Returns are deeply negative, including ROA, ROE, and ROIC, indicating no current economic moat in earnings power.

Balance Sheet Resilience

Liquidity is very strong, with a current ratio above 17x and cash per share exceeding book value per share.

Debt appears minimal, supporting near-term resilience despite weak profitability.

Cash Generation Capital Efficiency

TTM operating cash flow and free cash flow are negative, so the business is not currently self-funding.

Capital efficiency is poor, with negative cash-flow-based returns and no visible reinvestment advantage.

Moat Durability Intangibles

No signs of structural moat sources such as brand, switching costs, or scale economies in the current data.

The business appears highly commoditized based on flat zero margins and weak returns.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Whitehawk Therapeutics Inc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →